{"id":40972,"date":"2022-04-08T11:02:18","date_gmt":"2022-04-08T09:02:18","guid":{"rendered":"https:\/\/www.abcsg.org\/the-changing-treatment-landscape-of-cdk4-6-inhibitors\/"},"modified":"2026-02-05T11:13:06","modified_gmt":"2026-02-05T10:13:06","slug":"the-changing-treatment-landscape-of-cdk4-6-inhibitors","status":"publish","type":"post","link":"https:\/\/www.abcsg.org\/en\/the-changing-treatment-landscape-of-cdk4-6-inhibitors\/","title":{"rendered":"The Changing Treatment Landscape of CDK4\/6 Inhibitors<br \/>Moving From Late to Early Stages &#8211; 09 May 2022"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-30964\" src=\"https:\/\/www.abcsg.org\/wp\/wp-content\/uploads\/2022\/04\/CDK_4_6_Inhibitors_TEA_aun_1400x700_sRGB.jpg\" alt=\"The Changing Treatment Landscape of CDK4\/6 Inhibitors\" width=\"728\" height=\"364\" srcset=\"https:\/\/www.abcsg.org\/wp\/wp-content\/uploads\/2022\/04\/CDK_4_6_Inhibitors_TEA_aun_1400x700_sRGB.jpg 1400w, https:\/\/www.abcsg.org\/wp\/wp-content\/uploads\/2022\/04\/CDK_4_6_Inhibitors_TEA_aun_1400x700_sRGB-280x140.jpg 280w, https:\/\/www.abcsg.org\/wp\/wp-content\/uploads\/2022\/04\/CDK_4_6_Inhibitors_TEA_aun_1400x700_sRGB-768x384.jpg 768w\" sizes=\"auto, (max-width: 728px) 100vw, 728px\" \/><\/p>\n<p>Cyclin-dependent kinase (CDK) 4\/6 inhibitors have emerged as an appealing targeted cancer therapy of patients with hormone receptor-positive breast cancer. Prior to the availability of CDK4\/6 inhibitors, standard first-line therapy for patients with HR+\/HER2- mBC was single-agent endocrine therapy. Currently three new selective CDK4\/6 inhibitors are in different stages of development. Also, mechanisms of resistance to CDK4\/6 inhibitors, biomarker analyses to better select patients who derive the greatest benefit from CDK4\/6 inhibitors, in both early and advanced settings, and more issues have been elucidated.<\/p>\n<p>In this virtual joint event with Novartis \u2013 which already takes place the second time \u2013 both ABCSG and Novartis global experts will discuss the drastically changing treatment landscape of CDK4\/6 inhibitors in different stages of breast cancer.<\/p>\n<p>Particularly the experts will debate on hot topics such as OS data and their significance for clinical routine and therapeutic decision-making, the profiling of intrinsic subtypes and the role of selectivity. Furthermore, preclinical studies will be dissected on their efficacy, prospective research directions as well as co-targeting therapy strategies to overcome CDK4\/6 inhibitor resistance through SERDS will be outlined and discussed.<\/p>\n<p><strong>The Changing Treatment Landscape of CDK4\/6 Inhibitors: Moving From Late to Early Stages \u2013 09 May 2022<\/strong><\/p>\n<p>Monday, May 09, 2022<br \/>\nvirtual event (6.00-8.00 pm CET)<\/p>\n<p><a href=\"https:\/\/www.abcsg.org\/wp\/wp-content\/uploads\/2022\/04\/CDK_4_6_Inhibitors_Program_aun_qr_k_sV.pdf\" target=\"_blank\" target=\"_blank\" rel=\"noopener\">Please find the program here<\/a><\/p>\n<p>Das on-demand Video zum Event finden Sie ab sofort im <a href=\"https:\/\/www.abcsg.org\/login\/the-changing-treatment-landscape-of-cdk4-6-inhibitors-moving-from-late-to-early-stages\/\">ABCSG Members-Bereich<\/a><\/p>\n<p><a href=\"https:\/\/eventmaker.at\/universimed\/the_changing_treatment__landscape_of_cdk46_inhibitors\/anmeldung.html\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-30962 size-full\" src=\"https:\/\/www.abcsg.org\/wp\/wp-content\/uploads\/2022\/04\/CDK_4_6_Inhibitors_BAN_reg_728x90_sRGB.png\" alt=\"The Changing Treatment Landscape of CDK4\/6 Inhibitors\" width=\"728\" height=\"90\" srcset=\"https:\/\/www.abcsg.org\/wp\/wp-content\/uploads\/2022\/04\/CDK_4_6_Inhibitors_BAN_reg_728x90_sRGB.png 728w, https:\/\/www.abcsg.org\/wp\/wp-content\/uploads\/2022\/04\/CDK_4_6_Inhibitors_BAN_reg_728x90_sRGB-280x35.png 280w\" sizes=\"auto, (max-width: 728px) 100vw, 728px\" \/><\/a><\/p>\n<p>This event will be approved with 3 DFP points for Medical Education from the Austrian Medical Chamber also you\u2019ll receive a certificate of participation if requested.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cyclin-dependent kinase (CDK) 4\/6 inhibitors have emerged as an appealing targeted cancer therapy of patients with hormone receptor-positive breast cancer. Prior to the availability of CDK4\/6 inhibitors, standard first-line therapy for patients with HR+\/HER2- mBC was single-agent endocrine therapy. Currently three new selective CDK4\/6 inhibitors are in different stages of development. Also, mechanisms of resistance [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":30965,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[541],"tags":[563],"class_list":["post-40972","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-archiv-veranstaltungen-en","tag-cdk4-6-inhibitors-en"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-26 16:12:58","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/posts\/40972","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/comments?post=40972"}],"version-history":[{"count":1,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/posts\/40972\/revisions"}],"predecessor-version":[{"id":40973,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/posts\/40972\/revisions\/40973"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/media\/30965"}],"wp:attachment":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/media?parent=40972"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/categories?post=40972"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/tags?post=40972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}